biotech / news / / Benzinga
Regeneron will tie Medicaid drug pricing to benchmarks in other developed countries.
Regeneron will tie Medicaid drug pricing to international benchmarks under a new White House agreement.
KEY POINTS
- Praluent will be available for direct purchase at a most-favored-nation price on TrumpRx.gov.
- Regeneron will provide its FDA-approved hearing loss gene therapy, Otarmeni, free in the U.S.
- The agreement grants Regeneron three years of tariff relief in exchange for domestic investment commitments.
COMPANIES
Summarized by Newsio from Benzinga. How we summarize →